SG11202105506UA - Combination therapies for high and very high risk mds - Google Patents

Combination therapies for high and very high risk mds

Info

Publication number
SG11202105506UA
SG11202105506UA SG11202105506UA SG11202105506UA SG11202105506UA SG 11202105506U A SG11202105506U A SG 11202105506UA SG 11202105506U A SG11202105506U A SG 11202105506UA SG 11202105506U A SG11202105506U A SG 11202105506UA SG 11202105506U A SG11202105506U A SG 11202105506UA
Authority
SG
Singapore
Prior art keywords
combination therapies
risk mds
high risk
mds
therapies
Prior art date
Application number
SG11202105506UA
Other languages
English (en)
Inventor
Richard Ghalie
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of SG11202105506UA publication Critical patent/SG11202105506UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202105506UA 2018-11-30 2019-11-26 Combination therapies for high and very high risk mds SG11202105506UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773490P 2018-11-30 2018-11-30
PCT/US2019/063360 WO2020112848A1 (fr) 2018-11-30 2019-11-26 Polythérapies pour mds à haut et très haut risque

Publications (1)

Publication Number Publication Date
SG11202105506UA true SG11202105506UA (en) 2021-06-29

Family

ID=70854408

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105506UA SG11202105506UA (en) 2018-11-30 2019-11-26 Combination therapies for high and very high risk mds

Country Status (14)

Country Link
US (1) US20220016082A1 (fr)
EP (1) EP3886865A4 (fr)
JP (1) JP2022511746A (fr)
KR (1) KR20210097157A (fr)
CN (1) CN113412115A (fr)
AU (1) AU2019389004A1 (fr)
BR (1) BR112021010101A2 (fr)
CA (1) CA3121188A1 (fr)
EA (1) EA202191503A1 (fr)
IL (1) IL283464A (fr)
MA (1) MA54322A (fr)
MX (1) MX2021006127A (fr)
SG (1) SG11202105506UA (fr)
WO (1) WO2020112848A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
ES2774296T3 (es) * 2012-10-30 2020-07-20 Mei Pharma Inc Terapias de combinación para tratar cánceres quimiorresistentes
US10052346B2 (en) * 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids

Also Published As

Publication number Publication date
MA54322A (fr) 2021-10-06
EP3886865A4 (fr) 2022-11-23
IL283464A (en) 2021-07-29
US20220016082A1 (en) 2022-01-20
EP3886865A1 (fr) 2021-10-06
CA3121188A1 (fr) 2020-06-04
WO2020112848A1 (fr) 2020-06-04
JP2022511746A (ja) 2022-02-01
KR20210097157A (ko) 2021-08-06
EA202191503A1 (ru) 2021-11-15
BR112021010101A2 (pt) 2021-08-24
CN113412115A (zh) 2021-09-17
AU2019389004A1 (en) 2021-07-15
MX2021006127A (es) 2021-06-23

Similar Documents

Publication Publication Date Title
ZA202102016B (en) Combination therapies
IL271011A (en) Triple combination antibody treatments
IL274407A (en) Combined treatments
IL273510A (en) Combined treatments and their use
EP3612181A4 (fr) Thérapies d'association avec des inhibiteurs d'ehmt2
HK1254953A1 (zh) 抗vista抗體和片段
IL263680A (en) Combination of treatments
EP3328377A4 (fr) Compositions et méthodes pour thérapies immuno-oncologiques
IL291659A (en) Combined treatments
EP3849535A4 (fr) Polythérapies
IL270511A (en) Combined treatments using niraparib and pembrolizumab for the treatment of cancer
EP3697442A4 (fr) Polythérapies pour le traitement du cancer
ZA202102015B (en) Combination therapies
EP3849536A4 (fr) Polythérapies
EP3849534A4 (fr) Polythérapies
EP3548064A4 (fr) Anticorps anti-hrs et polythérapies pour le traitement de cancers
EP3860609A4 (fr) Polythérapies
ZA202102727B (en) Immunoablative therapies
HK1243598A1 (zh) 聯合治療
EP3849537A4 (fr) Polythérapies
EP3601363A4 (fr) Alt-803 combiné à un anticorps anti-cd38 pour thérapies anticancéreuses
EP3876988A4 (fr) Thérapies ciblant la cdcp1
IL281132A (en) Combination therapies that include PD-1-based chimeric proteins
GB2580963B (en) Cancer therapies
EP3849310A4 (fr) Polythérapies anticancéreuses